Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD, discuss the use of beta-blocker therapy following acute MI ...

The prevalence of acute myocardial infarction (AMI) in people with epilepsy increased from 2008 to 2017, according to a study ...

A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said ...

The prevalence of acute myocardial infarction (AMI) in people with epilepsy increased from 2008 to 2017, according to a study ...

(Editor's note: The NCDR-Action Registry will incorporate and replace the National Registry of Myocardial Infarction, which has collected data on more than 2.3 million acute MI patients and helped ...

The benefits of complete revascularization over culprit-only coronary artery revascularization were confirmed in older patients with ST-segment elevation myocardial infarction (STEMI) and ...

The cardiovascular safety of interrupting beta-blocker could not be shown in comparison to continuation in patients with a history of myocardial infarction (MI) and there was no benefit to the ...

JPI-289 is under clinical development by Jeil Pharmaceutical and currently in Phase II for Myocardial Infarction.

In a large meta-analysis, complete revascularisation reduced cardiovascular events compared with culprit-only revascularisation in older patients with a myocardial infarction and multivessel disease ...

The primary outcome was a composite of death from cardiovascular causes (cardiovascular death) or nonfatal myocardial infarction assessed in a time-to-event analysis. A total of 1518 patients ...

Background In acute heart failure (HF), reduced cardiac output, vasoconstriction and congestion may damage the intestinal ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...